Among patients with BRAFV600E-mutant metastatic CRC, the combination of inhibitors of BRAF and EGFR, with or without MEK inhibition, has been shown to improve survival outcomes over standard-of-care chemotherapy108,109. The gene discussed is EGFR; the disease is colorectal carcinoma.